Belgium-based OncoDNA SA has provides a complete solution from tumor profiling (OncoDEEP) to liquid biopsy (OncoTRACE) helping oncologists with drug treatment options and efficacy monitoring, has recently finalized a collaboration agreement with Laboratoire Cerba, the European leader in specialized clinical pathology and medical biology laboratories.
OncoDNA has been seduced by Laboratoire Cerba’s aim at supporting health professionals by offering them an always up-to-date portfolio of in vitro diagnostic tests and by permanently improving its services. OncoDEEP sequencing cancer panels combined with the Package PLUS (a cancer specific package composed of different IHCs and other tests designed to analyze key proteins presence and activity, translocations, etc.) was perfectly fitting this constant improvement philosophy.
This collaboration agreement addresses Laboratoire Cerba’s international territories and confers them the opportunity to meet their international customers’ requests for cancer molecular characterization, providing them with OncoDEEP DX Plus and OncoDEEP Clinical Plus.
The Laboratoire Cerba proposes a panel of over 2000 tests and continuous development of new biomarkers as the core of the health care extension provided to clinical pathologists it serves, wherever in the world. They are collecting samples directly in over 35 countries in Europe, Africa and Middle East through a network of agencies sharing its values and requirements in terms of quality and medical service provided.
“We are very happy about this collaboration agreement which will contribute to offer the Oncologists an innovative approach for patients in multiple therapeutic failures for which recommendations no longer exist.” said Dr Sylvie Cado, CEO of Laboratoire Cerba.
OncoDNA’s aim is to provide medical innovations based on comprehensive sequencing of tumor genomes complemented with molecular pathology testing, in order to assist medical doctors in their treatment choices and/or provide better monitoring of the evolution of their patients’ tumor.
Michäel Herman, Chief Business Officer at OncoDNA, said: “We initiated contacts with Laboratoire Cerba last September and we have fast realized that a partnership would be very much beneficial for both companies: the possibility for Laboratoire Cerba to propose state-of-the-art oncology services to complete their portfolio and the opportunity for OncoDNA to get access to their wide, expert and strong international network of agencies."